蛋白尿阴性的糖尿病CKD患者的视网膜、肾脏及心血管长期预后

2012-04-10 范振光 肾脏病与透析肾移植

文献标题:Long-term retinal, renal and cardiovascular outcomes in diabetic chronic kidney disease without proteinuria. 文献出处:Nephrol Dial Transplant. 2012 Jan;27(1):310-7. 期刊影响因子:3.564     此研

文献标题:Long-term retinal, renal and cardiovascular outcomes in diabetic chronic kidney disease without proteinuria. 文献出处:Nephrol Dial Transplant. 2012 Jan;27(1):310-7. 期刊影响因子:3.564
    此研究先通过一项横断面调查比较了蛋白尿阴性和阳性的DM + CKD患者之间的不同特点,然后进行随访,观察随后十多年来这些患者的心血管疾病,肾和视网膜的预后情况。

    先根据存在(n = 129)或不存在(n = 284)DM进行分层,各阶层有三组,即:无CKD组,CKD不合并蛋白尿组,CKD合并蛋白尿组。DM + CKD但无蛋白尿组与DM + CKD+蛋白尿组有着类似的临床特征,包括估计肾小球滤过率,但前者的24小时动态收缩压和舒张压低于后者。DM(-)组CKD(-),蛋白尿阴性的CKD患者,显著蛋白尿的CKD患者的全因死亡率分别为29.3,68.5和111.1 /1000患者年;而此数据在DM(+)组中分别为50.1,105.7和136.8 /1000患者年。在进行了多变量校正后,糖尿病仍有增加冠心病事件(P = 0.01)和终末期肾脏疾病(P = 0.05)的风险。 蛋白尿能够加重心血管事件,终末期肾病,死亡事件的风险,且使上述事件发生时间提前,这在有无糖尿病患者之间无显著差异。对于蛋白尿阴性的CKD患者, DM者发展成为显性蛋白尿的风险要高于非DM者[调整后的危险比5.28,95%可信区间为(1.64-17.02),P<0.01]。 CKD是视网膜病变的危险因素;蛋白尿是糖尿病视网膜病变的危险因素。

    所以,为了保护视力,蛋白尿(+)患者和糖尿病患者需要定期做视网膜检查。 由于无蛋白尿糖尿病CKD患者更可能发展显性蛋白尿,所以对他们进行密切随访,控制危险因素,显得格外重要。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645547, encodeId=f24f164554e7d, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Mon Dec 17 12:45:00 CST 2012, time=2012-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768819, encodeId=5f011e6881980, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Fri Jun 15 21:45:00 CST 2012, time=2012-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269765, encodeId=70ce1269e65ad, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645547, encodeId=f24f164554e7d, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Mon Dec 17 12:45:00 CST 2012, time=2012-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768819, encodeId=5f011e6881980, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Fri Jun 15 21:45:00 CST 2012, time=2012-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269765, encodeId=70ce1269e65ad, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1645547, encodeId=f24f164554e7d, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Mon Dec 17 12:45:00 CST 2012, time=2012-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768819, encodeId=5f011e6881980, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Fri Jun 15 21:45:00 CST 2012, time=2012-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269765, encodeId=70ce1269e65ad, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]

相关资讯

Diabetes Care:糖尿病患者高脉压和蛋白尿显著相关

  在日本总人群中,高脉压差和蛋白尿之间的相关性在糖尿病、糖尿病前期和糖耐量正常的人群之间存在显著性差异。仅糖尿病患者的高脉压差和蛋白尿存在显著相关。研究在2012年4月3日在线发表于《糖尿病护理》(Diabetes Care)杂志。   该研究旨在评价对于糖尿病、糖尿病前期或糖耐量正常受试者,高脉压差与蛋白尿之间的相关性,独立于其他血压(BP)指数(例如收缩压或舒张压)后,是否存在显著差异。